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Abstract
Background: The aim of this paper was undertake a systematic review and meta-analysis of the
use of spinal cord stimulation (SCS) in the management of refractory angina.
Methods: We searched a number of electronic databases including Medline, Embase and
Cochrane Library up to February 2008 to identify randomised controlled trials (RCTs) reporting
exercise capacity, ischemic burden, functional class, quality of life, usage of anti-anginal medication,
costs and adverse events including mortality. Results were reported both descriptively for each
study and using random effects meta-analysis. Given the variety in outcomes reported, some
outcome results were pooled as standardised mean differences (SMD) and reported in standard
deviation units.
Results: Seven RCTs were identified in a total of 270 refractory angina patients. The outcomes of
SCS were found to be similar when directly compared to coronary artery bypass grafting (CABG)
and percutaneous myocardial laser revascularisation (PMR). Compared to a 'no stimulation'
control, there was some evidence of improvement in all outcomes following SCS implantation with
significant gains observed in pooled exercise capacity (SMD: 0.76, 0.07 to 1.46, p = 0.03) and health-
related quality of life (SMD: 0.83, 95% CI: 0.32 to 1.34, p = 0.001). Trials were small and were
judged to range considerably in their quality. The healthcare costs of SCS appeared to be lower
than CABG at 2-years follow up.
Conclusion: SCS appears to be an effective and safe treatment option in the management of
refractory angina patients and of similar efficacy and safety to PMR, a potential alternative
treatment. Further high quality RCT and cost effectiveness evidence is needed before SCS can be
accepted as a routine treatment for refractory angina.
Background
The term 'refractory angina' is defined as "a chronic con-
dition caused by clinically established reversible myocar-
dial ischemia in the presence of coronary artery disease,
which cannot be adequately controlled by a combination
of medical therapy, angioplasty or coronary artery bypass
operations" [1]. Both increasing success and innovation
in conventional approaches to treat angina and better sur-
vival rates following primary and subsequent coronary
events have led to significant proportions of patients pre-
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It is estimated that in Europe the incidence of refractory
angina is 100.000 new cases per year [2].
For this patient group, a number of non-conventional
treatment options have emerged including, pharmaco-
therapy, enhanced external counterpulsation, percutane-
ous myocardial laser revascularisation (PMR),
percutaneous coronary artery bypass (CABG), and spinal
cord stimulation (SCS) [1,3].
First described for angina in 1987, SCS, is a reversible pro-
cedure in which electrodes are implanted in the epidural
space to stimulate the dorsal columns of the spinal cord
[4]. The technique has been described in detail elsewhere
[4,5]. SCS has been successfully used to relieve pain in a
number of chronic conditions including neuropathic pain
and peripheral vascular disease [5-7].
Published reviews have suggested the clinical efficacy of
SCS in refractory angina [8-12]. SCS has been shown to
provide chronic refractory angina patients with sympto-
matic relief that is equivalent to CABG, with lower rates of
complications and re-hospitalisation. Despite these con-
clusions and a level B (evidence class IIb) recommenda-
tion in 2002 American College of Cardiology; American
Heart Association (ACC/AHA) guidelines concerning
chronic stable angina [13] and a level A recommendation
by European Society of Cardiology (ESC) Joint Study
Group on the treatment of refractory angina [1], the tech-
nique has had little adoption by the cardiology commu-
nity [10]. One reason may be the absence to date of an
authorative review incorporating a meta-analysis of exist-
ing evidence.
The aim of this study was to undertake systematic review
and meta-analysis of randomised controlled trials (RCTs)
to assess the efficacy, safety and cost effectiveness of SCS
in patients with refractory angina.
Methods
The review was undertaken in accord with the methods of
The Cochrane Collaboration [14].
Search strategy
The following electronic databases were searched:
MEDLINE (Ovid) 1950 – January week 5 2008, MEDLINE
In Process and other Non-Indexed citations (Ovid) at Feb-
ruary 08 2008, EMBASE (Ovid) 1980 – 2008 week 6,
Cochrane Library (Wiley) 2008 Issue 1 (CDSR, DARE,
CENTRAL, NHS EED, HTA databases). The metaRegister
(Current Controlled Trials) and ClinicalTrials.gov were
searched to identify ongoing and unpublished research.
Internet sites of national and international health tech-
nology assessment organisations were also searched. We
sought unpublished literature by searching the Internet
sites of regulating authorities (Food and Drug Administra-
tion, and European Medicines Evaluation Agency) and by
contacting experts in the field.
The search strategy was developed to maximise the sensi-
tivity of article identification. We incorporated both con-
trolled vocabulary (e.g., Medical Subject Headings
[MeSH]) and key words ('refractory angina pectoris and
[synonym]' and 'spinal cord stimulation or neuromodula-
tion or [synonym]'). An example search strategy is shown
in Appendix 1.
Inclusion criteria and data extraction
Studies were considered eligible if they were RCTs (paral-
lel or cross over); included patients with refractory angina
(according to pre-defined clinical criteria) and received
SCS (either alone or in combination with other thera-
pies). Three categories of outcome were sought i.e. efficacy
– exercise capacity, ischemic burden (combined frequency
and severity of ischemic changes during ambulatory ECG
monitoring), anti-anginal drug consumption, functional
class and health-related quality of life; safety – mortality,
morbidity and SCS-related complications; and healthcare
utilisation or costs. No language restrictions were applied
in the selection of studies. Non-randomised studies were
excluded as were studies that reported only physiological/
experimental outcomes (e.g. myocardial blood flow) or
studies using transcutaneous electrical nerve stimulation.
Two reviewers undertook study selection and data extrac-
tion using a standardised data proforma. Where multiple
time points were reported, all follow up data were consid-
ered. Study authors were contacted to seek clarification on
issues of reporting or to provide further outcome details.
Risk of bias assessment
Each included trial was evaluated with regard to whether
there was an appropriate method of randomisation (e.g.,
statement of computer-generated numbers) and an ade-
quate concealment of randomisation (e.g., randomisation
codes been kept from those involved in running the trial),
whether there was blinding (particularly blinding of out-
come given the difficulties of blinding patients as the
result of parasthesia), whether the losses to follow-up/
drop-outs were reported and if so, whether this rate was <
20%, and whether an intention-to-treat (ITT) analysis was
performed [14]. If a trial did not report these parameters,
then the criteria were judged as unmet (i.e., 'not reported',
NR). In additional to a qualitative assessment, a total risk
of bias score was obtained using a modified version of the
Jadad scale [15]. Risk of bias was assessed by two inde-
pendent reviewers.Page 2 of 13
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Findings of this review are presented according to the two
broad categories of control group i.e. SCS versus active
intervention (i.e. CABG or PMR) and active SCS ('SCS
ON') versus no or inactive SCS ('SCS OFF'). A two stage
approach to data synthesis was taken. First the findings of
all the studies were summarised qualitatively according to
their direction of effect and statistical significance of both
within group differences (i.e. comparison of outcome at
baseline and follow up in the SCS and control groups)
and between group difference (i.e. comparison of out-
comes in SCS group versus control group). If the within
group change was not reported in the source paper, it was
calculated making allowance for the within-patient corre-
lation from baseline to follow-up measurements [14,16].
Results were only used from the first period of cross-over
trials [14].
The between group differences of active SCS ('SCS ON')
versus no or inactive SCS ('SCS OFF') trials were therefore
quantitatively pooled using meta-analysis. A conservative
Der Simonian random effects meta-analysis model was
used to take account of the potential heterogeneity (both
clinical and methodological) across trials [17]. Given the
variety of outcome measures reported, results were
expressed as a standardised mean difference (SMD). SMD
is a summary statistic used when trials assess the same
outcome, but measure it in a variety of ways (for example,
all trials measure quality of life but they use different
scales) [14]. The SMD expresses the size of the treatment
effect in each trial relative to the study variance or stand-
ard deviation observed in the trial. To prevent the risk of
carry over effects, only the first period of cross-over trials
were included and the variance modified to take account
of the paired nature of the between group comparison
[14]. Funnel plots (i.e. scatter plots of the mean interven-
tion effect versus the inverse of variance of the interven-
tion effect for each study) was used to explore the
possibility of publication bias [18]. All analyses were per-
formed using RevMan, version 5.0 http://www.cc-
ims.net/RevMan.
Results
Identification and selection of studies
Our bibliographic search yielded 385 titles. After review-
ing these titles and abstracts, 67 full papers were retrieved
for possible inclusion. Most abstracts and titles or full
papers were excluded on the basis of an inappropriate
intervention or that they were case reports. Eleven publi-
cations across seven RCTs (a total of 270 patients) were
judged to meet the inclusion criteria (see Figure 1) [19-
29]. The RCT of Lanza et al was excluded on grounds that
it was based on patients with Syndrome X [30].
Description of randomised controlled trials
Two studies compared SCS to an alternative active inter-
vention: CABG – ESBY trial [19-22], and PMR – SPiRiT
trial [23]. Four studies compared active SCS ('SCS ON') to
inactive SCS ('SCS OFF') (DiPede et al, 2001 [26]; Hauvast
et al, 1998 [27]; Jessurun et al, 1999 [28], Eddicks et al,
2007 [29]) and one study compared SCS to a control
group receiving no SCS implantation (DeJongste et al,
1993 [[24], 35]) (see Table 1). Eddicks et al randomised
patients into three SCS stimulation groups (i.e. 3 × 2
hours/day, 24 hours/day with conventional output, 3 × 2
hours/day with a subthreshold output) and control (24
hours/day with 0.1 volts) [29]. For the purposes of this
review, the results from 3 × 2 hours/day group were used.
Three studies were conducted in the same centre. One of
the authors of this review (MdeJ) was an investigator in
these studies and confirmed that there was no overlap in
patents.
All studies were conducted in European centres and were
single centre. Patient inclusion criteria appeared similar
across studies i.e. all had experienced refractory angina in
spite of optimal medical therapy and unable to undergo
revascularisation, and angina class NHYA class III and IV
or Canadian Cardiovascular Society (CCS) class 3 and 4.
Included patients were predominantly male (63%) with a
median age of 63.5 years, the majority of whom had expe-
rienced a previous myocardial infarction (median 73%).
The majority of trials were of short term follow up (i.e. ≤
2 months), the SPiRiT and ESBY studies reporting follow
up of 1 year or longer.
Risk of bias
The limited level of reporting method detail by many
included studies hampered the full assessment of their
risk of bias (see Table 2). Only one trial provided details
of random sequence generation and two trials reported
the method of allocation concealment. Although four
studies employed a 'SCS ON' vs. 'SCS OFF' cross over
design blinding is likely to have been prevented by
patient's perception of paraesthesia. One study achieved
double blinding by employing a very low stimulus control
group (0.1 v 24 hours per day) [29]. One study reported
blinded ECG outcome assessment [26]. There was little
evidence of attrition bias, all studies reporting follow up
on 90% or more of patients randomised. The median
Jadad score was 2 (range, 2 to 4, out of a maximum score
of 5) indicating overall, a moderate level of risk of bias.
Outcomes
Exercise capacity
Six studies assessed exercise capacity, reporting outcomes
using a number of metrics (e.g. exercise duration, maxi-
mum oxygen uptake and peak workload) [19,23,24,27-
29]. Of the four studies that reported the within group dif-Page 3 of 13
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SCS, three found a statistically significant improvement in
exercise capacity (Table 3). Although in the ESBY study no
significant change in maximum work capacity was
observed 6-months post-implant, SCS was inactivated
during the exercise test. As shown in Figure 2, in the
pooled analysis there was a superior exercise capacity with
active SCS compared to no SCS or SCS OFF (SMD: 0.76,
0.07 to 1.46, p = 0.03, heterogeneity test: χ2 = 7.4, p =
0.06, I2 = 60%). Compared to both CABG and PMR no
significant difference was seen in exercise capacity scores
at follow up. However, when adjusted for baseline values,
the ESBY trial authors did report a small difference in exer-
cise capacity at follow up in favour of CABG (p = 0.03).
Ischemic burden
Ischemic burden (i.e. frequency and magnitude of ST-
depression over 24-hour or 48-hour ECG monitoring)
was assessed in four studies [19,26-28]. In the two studies
that reported the between group change in ischemic bur-
den following SCS implantation, one reported a signifi-
cant improvement at follow up while the other reported
no change (Table 3). There was no significant difference in
pooled ischemic burden at follow up between SCS and
CABG (SMD: 0.19, 95% CI: -0.29 to 0.67, p = 0.44, see
Figure 3) while there was a trend towards a lower ischemic
burden with SCS compared to no SCS or SCS OFF (SMD:
-0.34, 95% CI: -0.80 to 0.12, p = 0.12, Figure 3).
Nitrate drug consumption
Five studies reported the consumption of shorting acting
nitrates (GTN) [19,24,28,29]. All three studies reporting
the between group change reported a significant reduction
in GTN following SCS (Table 3). As shown in Figure 4
although the pooled analysis showed some evidence of
lower level of GTN usage with SCS compared to no SCS/
SCS OFF (SMD -0.74, 95% -1.74 to 0.27, p = 0 15, Test of
heterogeneity; χ2 = 7.7, p = 0.02, I2 = 74%) this difference
did not achieve statistical significance. There was no dif-
ference in nitrate consumption compared to CABG at 6-
months or 2-years follow up (see Figure 4).
Functional class
Two studies reported the change in CCS class. The SPiRiT
study found a lower CCS class at 3 and 12-months follow
up in SCS treated patients compared to patients receiving
PMR (3-months: p = 0.049; 12-months; p = 0.093) [23].
Eddicks et al reported a mean CCS of 1.6 in patients when
receiving SCS (3–5.5 V 3 × 2 hours per day) compared to
control treatment (0.1 V 24 hours per day) mean CCS of
3.1 (p = 0.002) [30].
Health- related quality of life
Five studies assessed health-related quality of life using
validated instruments that included both generic (e.g.
Short-Form 36, Nottingham Health Profile & EuroQoL
(or EQ-5D)) and disease specific measures (Seattle Angina
Questionnaire & Quality of Life Questionnaire – Angina
Pectoris) [21,23,24,27,29]. The four studies that reported
outcome at baseline and follow up, each found a signifi-
cant improvement in quality of life (both generic and dis-
ease specific) with SCS (Table 3). Based on aggregate
scores, pooled quality of life was superior for SCS com-
pared to no SCS or SCS OFF (SMD: 0.83, 95% CI: 0.32 to
1.34, p = 0.001; Test of heterogeneity: χ2 = 0.9, p = 0.65, I2
= 0%). There was no significant difference in quality of life
with SCS compared to either CABG or PMR (see Figure 5).
Adverse events SCS-related complications
Four studies reported data on SCS-related complications
and adverse outcomes including cardiac events and treat-
ment cross over (see Table 4) [19,23,25,27,29]. SCS-
reported related complications included infections (1 out
104 patients, 1.0%) and lead migration or fracture (10 out
of 128 patients, 7.8%). The risk of non-fatal events, fatal
events and treatment cross-over appeared similar for SCS
to that of PMR at 1 and 2-years follow up [23]. In the ESBY
study, morbidity was comparable between the groups,
however, total mortality was somewhat higher in the
CABG group than with SCS (6 months follow up: 7/51 vs.
Summary of study selection and exclusion processFigure 1
Summary of study selection and exclusion process.
Titles identified from 
bibliographic databases 
N = 385 
Excluded on basis 
of title or abstract 
N = 318 
Full papers retrieved 
for assessment 
N = 67 
``
Excluded 
Case series N = 25; inappropriate 
outcomes N = 3 
Not refractory angina or SCS N = 28
Included RCTs 
N = 7 
(N =11 papers) Page 4 of 13
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Table 1: Summary of included RCT characteristics
Trial Name/
author
Year, country
Setting
Design
Recruitment 
dates
Population
Age – Mean (SD or range)
Sex – % male
Class
Inclusion criteria
Intervention
N patients
Control
N patients
Relevant outcomes Follow up*
de Jongste et 
al24,25
1994, 
Netherlands
Single Centre
Parallel RCT
Jan 1990 to 
March 1992
60 years (5)
71% male
NYHA III/IV
Angiographically confirmed CAD not 
suitable for revascularisation. Reversible 
ischemia on exercise. Receiving optimal 
drug therapy.
SCS
N = 12
No SCS
N = 10
Primary outcome: exercise 
capacity (treadmill time).
Secondary outcomes: health 
related quality of life, nitrate 
drug usage, ischemic burden & 
adverse events
2-months
Di Pede et al26
2001, Italy
Single Centre
Cross over RCT
Oct 1990 to Sept 
1998
76 yrs (8)
60% male
CCS 3/4
Severe angina despite optimal drug 
treatment. Revascularisation not possible. 
Reversible ischemia on exercise.
SCS ON
N = 15
SCS OFF
N = 15
Ischemic burden 48-hours
ESBY19–22
1998, Sweden
Single centre
Parallel group 
RCT
Oct 1990 to Sept 
1998
68.9 yrs (40–82)
80% male
AHA angina class 3/4
Symptomatic indication for CABG & no 
prognostic benefit from CABG
SCS
N = 53
CABG
N = 51
Primary outcomes: exercise 
capacity (workload), angina 
attacks
Secondary outcomes: nitrate 
drug usage, ischemic burden, 
health-related quality of life, 
morbidity, mortality & 
complications
6-months, 2-
years, 5-years
Hautvast et al27
1998, 
Netherlands
Single Centre
Parallel group 
RCT
Not reported
62.5 yrs (7.5 years)
56% male
NYHA class III/IV
Angiographically confirmed CAD not 
suitable for revascularisation with proven 
ischemia. Reversible ischemia on 
exercise. Receiving optimal drug therapy.
SCS ON
N = 13
SCS OFF
N = 12
Exercise capacity (treadmill 
time), angina attacks, nitrate 
drug usage & health-related 
quality of life
1.5 months
Jessurun et al28
1999, 
Netherlands
Single Centre
Parallel group 
RCT
Not reported
59 yrs (5.5)
67% male
NYHA class III/IV
Unresponsive to optimal medication. 
Revascularisation not possible. Reversible 
ischemia on exercise or equivalent
SCS ON
N = 12
SCS OFF
N = 12
Exercise capacity (treadmill 
V02max), ischemic burden, & 
nitrate drug usage
1-month
SPiRiT
2006, UK
Single centre
Parallel group 
RCT
Dec 2000–Dec 
2003
63.5 yrs (8)
88% male
CCS class 3/4
Limiting angina despite optimal drug 
therapy. Angiography confirmed CAD 
and reversible ischemia on radionuclide 
scanning
SCS
N = 34
Percutaneous 
myocardial 
laser 
revascularisati
on (PMR)
N = 34
Primary outcome: exercise 
capacity (treadmill time). 
Secondary outcomes: 
functional class, mortality, 
quality of life, morbidity, 
mortality & complications
3-months, 12 
months
Eddicks et al29
2007, Germany
Single centre
Cross over RCT
June 2003 to 
August 2004
65 yrs (8)
67% male
CCS 3/4
Proven responders to SCS, angina > 3 
months, known CAD, reversible 
myocardial ischemia, receiving optimal 
drug therapy with no benefit from 
revascularisation
SCS ON1
N = 12
SCS OFF2
N = 12
Primary outcome: exercise 
capacity (6-min walk test)
Secondary outcomes: number 
of angina attacks, health-
related quality of life (Seattle 
Angina Questionnaire), CCS 
class, nitrate drug usage, drop 
out due to intolerable 
symptoms
4 weeks
*: follow up related to randomised comparison; CCS: Canadian Cardiovascular Scale; AHA: American Heart Association; CABG: coronary artery 
bypass graft.
1. consisted of 3 SCS states – stimulation for 3 × 2 h/day with conventional output, 24 h/day with conventional output, 3 × 2 h/day with 
subthreshold output
2. stimulation for 24 h/day with 0.1 V output
BMC Cardiovascular Disorders 2009, 9:13 http://www.biomedcentral.com/1471-2261/9/131/53, p = 0.02; 2 years follow up: 10/53 CABG 5/53, P =
0.16; 5 years follow up 16/51 vs. 13/53, p > 0.05) [19].
Healthcare utilisation and costs
Only one trial reported the use of healthcare resources and
costs [18]. The ESBY trial reported healthcare utilisation
and costs at 2-years follow up. The overall number of days
of hospitalisation in patients receiving SCS (mean 5.0
days) was lower compared to those having undergone
CABG (mean: 11.1 days, p < 0.0001). Taking into account
the cost of the primary intervention, hospital days and fol-
low up treatments and visits the average cost was 16,400
Euros per patient with SCS compared to 18,800 Euros per
patient with CABG (p < 0.01).
Discussion
To the author's knowledge this is the first published meta-
analysis of SCS for the treatment of refractory angina.
We found seven RCT's of SCS recruiting a total of 270
patients. The inclusion criteria and patients characteristics
of these trials were broadly similar i.e. NYHA class III and
IV patients, predominantly male and post-myocardial inf-
arction, experiencing angina in spite of optimal medical
therapy with no foreseen benefit from CABG. Of these,
two compared SCS to an active intervention (CABG or
PMR) and the remainder compared SCS to a 'no stimula-
tion' control. Meta-analysis showed that when compared
to a no stimulation control, SCS significantly improved
the exercise capacity and health-related quality of life of
this patient population. The magnitude of outcome
improvement with SCS appears to be similar to that of
CABG and PMR, although the relevance of CABG as a
treatment option for management of refractory angina is
questionable [1,3]. A proportion of patients experienced
SCS-related complications, in particular infections and
lead migration or breakage. However, these complications
are relatively minor and correctable. It has been suggested
that SCS may mask angina symptoms and therefore
increase the cardiac risk [9]. However, we found no
increase in cardiac morbidity or mortality with SCS when
compared to other treatments. This has also been reported
in observational studies [9-12].
Mechanism of action
The mechanism of action of SCS is not yet completely
understood. A recent review of experimental studies pro-
vides a summary of putative mechanisms [21]. The bene-
fits to the heart are not likely only to be due to an increase
in blood flow. As recently shown, a redistribution of local
blood flow may very well be responsible for the improve-
ment in myocardial ischemia [9]. SCS is also associated
with normalisation of the intrinsic cardiac nervous system
[31].
Limitations
The general lack of reporting of methods in the included
RCTs made it difficult to assess their methodological qual-
ity and thereby judge their risk of bias and potential to
overestimate the effect of SCS. One particular challenge of
SCS evaluation is the difficulty in patient blinding as the
therapy produces paraesthesia that must be elicited in the
area of the pain if SCS is to be efficacious. In addition, the
implantation procedure might in itself produce a placebo
effect, but sham operations are ethically difficult to justify
[32]. Thus a placebo effect of treatment cannot be com-
pletely excluded. However, it seems unlikely that a pla-
cebo effect alone would totally account for the clinical
benefits from SCS seen in this review, including improve-
ments in ischemic burden assessed by objective ambula-
tory ECG monitoring. By implanting a stimulator in both
groups, a number of studies minimised the risk of an
'operation bias' [27].
Table 2: Risk of bias and funding source
Random 
sequence 
generation
Concealment 
of 
randomisation
Blinding Loss to follow 
up/drop out
Method of 
data analysis
Jadad score 
(/5)
Funding
DeJongste 
1994
Not stated Independent 
telephone service
Open label 8% Not stated 2 Government
DiPede 2001 Not stated Not stated Blinded ECG 
assessment
0% Not stated 3 Not stated
ESBY 1998 Not stated Not stated Open label 7%* Intention to 
treat
2 Government
Hauvast 1998 Not stated Not stated Open label 0% Not stated 2 Government
Jessurum 
1999
Not stated Not stated Open label 0% Not stated 2 Industry
SPiRiT 2006 Computer-
generated
Independent R&D 
department
Open label 9% Intention to 
treat
4 Industry
Eddicks 2007 Not stated Not stated Double blind 0% Not stated 4 Industry
*: at 6-months follow upPage 6 of 13
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to detect potentially important clinical differences
between treatments. In order to overcome this limitation,
we pooled the results of ON-OFF SCS trials. A random
effects meta-analysis approach was chosen to reflect both
the clinical and methodological across trials. However,
given the small number of trials we acknowledge that this
statistical approach may have underestimated the
between-trial variance resulting in the overall precision of
treatment effect being over estimated and the resulting p-
values from tests of treatment effects being too small.
Inevitably, any review can be subject to publication bias,
i.e. studies with 'positive' results are more likely to be
reported and published, while side effects and adverse
events are more likely to be underreported [14]. Funnel
plots (scatter plots of the treatment effects estimated from
individual studies against each study's sample size) can be
used to assess for the presence of publication bias i.e. the
absence of negative trials [18]. Given the small number of
RCTs it was difficult in this case to appropriately interpret
the funnel plots. However there was some evidence of
funnel plot asymmetry (not shown) in the most com-
monly reported outcomes in this review (i.e. exercise
capacity, ischemic burden and nitrate consumption).
Although such asymmetry can be indicative of publica-
tion bias (i.e. the absence of negative studies) it can also
reflect poor methodological quality of smaller studies,
true heterogeneity, size of effect differs according to study
size (for example, due to differences in the intensity of
interventions or differences in underlying risk between
studies of different sizes) and chance [18].
Clinical and future research implications
On balance, the finite evidence base of seven RCTs of
moderate quality identified by this review supports the
current 2007 ACC/AHA Grade IIb evidence classification
and their Level B recommendation for SCS in refractory
angina patients [13]. Given the relatively sparse evidence
base for alternative treatments, these results would sup-
port the more widespread use of SCS in the management
of refractory angina, particularly in the context of a clinical
trial.
Additional high quality RCT and collected in appropri-
ately selected patients is needed before SCS can be recom-
mended for the routine treatment of refractory angina. In
view of lack of consensus in the clinical community as to
how to best manage refractory angina any future trial will
need to carefully consider the choice of the comparator
therapies. Such a trial will also need also to examine the
question of value for money and therefore comprehen-
sively assess healthcare resource utilisation, costs, and col-
lect generic preference-based quality of life data such as
the EQ-5D. The recently published 24-month analysis of
the clinical and cost effectiveness of the SpiRiT trial pro-
vides a useful framework of the type of data analysis and
outcomes needed in the future for SCS [33].
Exercise capacity – between-group differenceFigure 2
Exercise capacity – between-group difference.
Study or Subgroup
1.1.2 SCS vs CABG
EBSY 1993
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
1.1.3 SCS vs PMR
SPiRiT 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
1.1.4 SCS ON vs SCS OFF
Jessurun 1999
Hauvast 1998
Eddicks 2007
DeJongste 1994
Subtotal (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 7.44, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.14 (P = 0.03)
Mean
92.2
7.3
14.6
19
394
827
SD
33.7
3.5
3.2
14
55
138
Total
53
53
32
32
12
13
12
8
45
Mean
99
7.3
15.3
-0.2
337
694
SD
28
3.8
3.4
17
55
67
Total
47
47
33
33
12
12
12
9
45
Weight
100.0%
100.0%
100.0%
100.0%
27.2%
25.7%
25.8%
21.4%
100.0%
IV, Random, 95% CI
-0.22 [-0.61, 0.18]
-0.22 [-0.61, 0.18]
0.00 [-0.49, 0.49]
0.00 [-0.49, 0.49]
-0.20 [-1.01, 0.60]
1.20 [0.33, 2.06]
1.00 [0.14, 1.86]
1.19 [0.13, 2.24]
0.76 [0.07, 1.46]
SCS Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours SCSPage 7 of 13
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Table 3: Qualitative summary of efficacy outcomes
A. SCS vs. active comparator studies
Trial Name/author Outcome Within group 
difference SCS
Within group difference 
Control
Between group 
difference SCS vs. 
control
ESBY 1998 (vs CABG) Nitrate drug usage 6-mo + 6-mo + 6-mo =
2-yr + 2-yr + 2-yr =
Exercise capacity 6-mo = 6-mo + 6-mo --
Total mortality NR NR 6-mo +
NR NR 2-yr =
NR NR 5-yr =
Non fatal morbidity NR NR 6-mo =
Ischemic burden 6-mo = 6-mo = 6-mo =
HRQoL (QLQ-AP & NHP) 6-mo + 6-mo + 6-mo =
2-yr + 2-yr + 2-yr =
6-mo + 6-mo+ 6-mo =
Angina
SpiRiT 2006* (vs PMR) Exercise capacity 3-mo + 3-mo = 3-mo =
12-mo = 12-mo = 12-mo =
CCS class 3-mo + 3-mo + 3-mo +
12-mo + 12-mo + 12-mo =
HRQoL (SF-36 & 3-mo + 3-mo + 3-mo =
SAQ)* 12-mo + 12-mo + 12-mo =
B. SCS vs no SCS/SCS OFF studies
Trial Name/author Outcome Within group 
difference SCS
Within group difference 
Control
Between group 
difference SCS vs. 
control
DeJongste 1994 Exercise capacity + = +
Nitrate drug usage + = +
HRQoL (ADL score) + = +
Hautvast 1998 Exercise capacity + = +
Nitrate drug usage + = =
HRQoL (LASA) + = =
Ischemic burden + = =
Jessurun 1999 Exercise capacity NR NR =
Ischemic burden NR NR =
Nitrate drug usage NR NR =
DiPede 2001 Eddicks 
2007
Ischemic burden NR NR =
Exercise capacity NR NR +
Nitrate drug usage NR NR +
HRQoL (SAQ) NR NR +/=
(EQ-5D) NR NR +
CCS class NR NR +
Angina attacks NR NR +
*additional data supplied by authors
HRQOL: health-related quality of life; ADL: activities of daily living score; SF-35: Short-form 36 questionnaire; NHP: Nottingham Health Profile; 
QLQ-AP: Quality of Life Questionnaire – Angina Pectoris; SAQ: Seattle Angina Questionnaire; SAS: Social Activity Scale; LASA: Linear Analogue 
Self Assessment; VAS – visual analogue scale; 6-MWT: 6 minute walk test; NR: not reported
+: within group – improvement (P ≤ 0.05) in outcome with SCS or control at follow up compared to baseline; between group – superior (P ≤ 0.05) 
outcome at follow up with SCS compared to control
-: within group – worsening (P ≤ 0.05) in outcome with SCS or control at follow up compared to baseline; between group – superior (P ≤ 0.05) 
outcome at follow up with control compared to SCS
=: within group – no change (P > 0.05) in outcome with SCS or control at follow up compared to baseline; between group – no difference (P > 0.05) 
outcome at follow up of SCS compared to control
BMC Cardiovascular Disorders 2009, 9:13 http://www.biomedcentral.com/1471-2261/9/13Conclusion
SCS appears to be an effective and safe treatment option
in the management of refractory angina patients and of
similar efficacy and safety to PMR, a potential alternative
treatment. Further high quality RCT and cost effectiveness
evidence is needed before SCS can be accepted as a routine
treatment for refractory angina.
Abbreviations
ACC: American College of Cardiology; AHA: American
Heart Association; CABG: coronary artery bypass surgery;
CCS: Canadian Cardiovascular Society; NYHA: New York
Heart Association; CI: confidence interval; ITT: intention
to treat; NR: not reported; PMR: percutaneous myocardial
laser revascularisation; SCS: spinal cord stimulation; RCT:
randomised controlled trial; SMD: standardised mean dif-
ference
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Ischemic burden – between-group differenceFigure 3
Ischemic burden – between-group difference.
Study or Subgroup
1.4.1 SCS vs active comparator
ESBY 1998
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
1.4.2 SCS ON vs SCS OFF
DiPede 2001
Hauvast 1998
Jessurun 1999
Subtotal (95% CI)
Heterogeneity: Chi² = 0.79, df = 2 (P = 0.67); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)
Mean
44.2
2.7
0
0
SD
124.2
4.1
31
18
Total
39
39
13
13
12
38
Mean
23.8
5.6
2.7
9
SD
78.5
6.8
61
18
Total
30
30
13
12
12
37
Weight
100.0%
100.0%
34.2%
34.1%
31.7%
100.0%
IV, Fixed, 95% CI
0.19 [-0.29, 0.67]
0.19 [-0.29, 0.67]
-0.50 [-1.28, 0.28]
-0.05 [-0.84, 0.73]
-0.48 [-1.30, 0.33]
-0.34 [-0.80, 0.12]
SCS Control Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours SCS Favours control
Nitrate drug consumption – between-group differenceFigur 4
Nitrate drug consumption – between-group difference.
Study or Subgroup
1.5.1 SCS vs Active comparator
ESBY 1998
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
1.5.2 SCS ON vs SCS OFF
DeJongste, 1994
Hauvast 1998
Jessurun 1999
Subtotal (95% CI)
Heterogeneity: Tau² = 0.58; Chi² = 7.71, df = 2 (P = 0.02); I² = 74%
Test for overall effect: Z = 1.43 (P = 0.15)
Mean
4.1
1.8
1.6
0
SD
10.1
2.1
2.2
0.7
Total
53
53
11
13
12
36
Mean
3.1
7.2
2.6
0
SD
8.7
3.3
1.7
0.7
Total
51
51
9
12
12
33
Weight
100.0%
100.0%
28.4%
35.8%
35.8%
100.0%
IV, Random, 95% CI
0.11 [-0.28, 0.49]
0.11 [-0.28, 0.49]
-1.92 [-3.02, -0.81]
-0.49 [-1.29, 0.31]
0.00 [-0.80, 0.80]
-0.74 [-1.74, 0.27]
SCS Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours SCS Favours controlPage 9 of 13
(page number not for citation purposes)
BMC Cardiovascular Disorders 2009, 9:13 http://www.biomedcentral.com/1471-2261/9/13international research team. None of the authors received
personal remuneration from this funding. The planning
of this study, interpretation of findings, writing and con-
clusions of manuscript were undertaken entirely inde-
pendently of the company interests.
MDeJ and JdeV declare no competing. EHC Hospital of
Morges (EB's employer) and RST have received financial
reimbursement as consultants for Medtronic.
Authors' contributions
RST, MdJ and JDeV conceived the study. RST analysed the
data. All authors participated in the interpretation of
results and drafting and approval of the manuscript.
Appendix 1. Search strategy
Database: Ovid MEDLINE(R) <1950 to January Week 5
2008>
1 electric stimulation therapy.mp. or exp Electric Stimula-
tion
Therapy/
2 exp Spine/
3 (spine or spinal or spines).mp.
4 or/2–3
5 1 and 4
6 scs.mp.
7 dorsal cord stimulat$.tw.
8 spinal cord stimulat$.tw.
9 neurostimulation.mp.
10 neuromodulation.mp.
11 or/5–10
12 angina pectoris.mp. or exp Angina Pectoris/
13 refractory angina.mp.
Health related quality of life – between-group differenceFigure 5
Health related quality of life – between-group difference. Based on NHP part 1 score for ESBY 1993; SF-36 physical 
health scale at 2-years for SPiRiT, 2006; ADL score for DeJongste 1994, EQ-5D VAS score for Eddicks 2008; LASA score for 
Hauvast 1998.
Study or Subgroup
1.3.1 SCS vs CABG
EBSY 1993
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
1.3.2 SCS vs PMR
SPiRiT 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
1.3.4 SCS ON vs SCS OFF
DeJongste, 1994
Eddicks 2007
Hauvast 1998
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.86, df = 2 (P = 0.65); I² = 0%
Test for overall effect: Z = 3.20 (P = 0.001)
Mean
15
29.8
2.1
56.3
6.8
SD
27
12.3
0.6
10
1
Total
45
45
31
31
8
12
13
33
Mean
18
24.7
1.25
45.9
6.2
SD
40
14.1
0.8
11
1.1
Total
45
45
29
29
9
12
12
33
Weight
100.0%
100.0%
100.0%
100.0%
27.0%
35.2%
37.8%
100.0%
IV, Random, 95% CI
-0.09 [-0.50, 0.33]
-0.09 [-0.50, 0.33]
0.38 [-0.13, 0.89]
0.38 [-0.13, 0.89]
1.13 [0.08, 2.18]
0.96 [0.10, 1.81]
0.55 [-0.25, 1.36]
0.83 [0.32, 1.34]
SCS Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Control Favours SCSPage 10 of 13
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15 or/12–14
16 11 and 15
17 randomized controlled trial.pt.
18 controlled clinical trial.pt.
19 randomized controlled trials.sh.
20 random allocation.sh.
21 double blind method.sh.
22 single-blind method.sh.
23 or/17–22
24 (animals not human).sh.
25 23 not 24
26 clinical trial.pt.
27 exp clinical trials/
28 (clin$ adj25 trial$).ti,ab.
29 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$)).ti,ab.
30 placebos.sh.
31 placebo$.ti,ab.
32 random$.ti,ab.
33 research design.sh.
34 or/26–33
35 34 not 24
36 35 not 25
37 comparative study.sh.
38 exp evaluation studies/
39 follow up studies.sh.
40 prospective studies.sh.
41 (control$ or prospectiv$ or volunteer$).ti,ab.
42 or/37–41
43 42 not 24
Table 4: Summary of safety outcomes – number of patient events
DeJongste 1994 Hauvast 1998 Eddicks 2007 ESBY 1998 SpiRiT 2006
Follow up 13.8 months 6-weeks 4 weeks 2-years 1-year
SCS-related complication
Infection NR 0/13 NR 1/57 0/34
Lead migration/fracture 6/34 0/13 NR 3/57 1/34
Mortality/morbidity
Non fatal MI 1/12 NR NR SCS 7/53
CABG 3/53, P = 0.18
SCS 4/34
PMR 1/34, P = 0.16
Total mortality 2/12 NR NR SCS 5/53
CABG 10/53, P = 0.16
SCS 4/34
PMR 2/34, P = 0.73
Cardiac mortality 2/12 NR NR SCS 3/53
CABG 5/53, P = 0.54
SCS 2/34
PMR 1/34, P = 0.52
Other outcomes
Treatment cross over NR NR NR 6-months
SCS 3/53
CABG 3/51
SCS 1/34
PMR 0/33
CABG: coronary artery bypass graft; PMR: percutaneous myocardial laser revascularisation; NR: not reportedPage 11 of 13
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45 25 or 36 or 44
46 16 and 45
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